Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cross-reactivity00:42

Cross-reactivity

31.5K
Overview
31.5K
Vaccinations01:51

Vaccinations

45.3K
Overview
45.3K
Cancer Vaccines01:30

Cancer Vaccines

509
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
509

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An innovative nasal nanovaccine against SARS-CoV-2 induces systemic and upper airway immunity controlling viral replication.

NPJ vaccines·2026
Same author

Molecular Characterization of Calu-3 Cells from Submerged to Air-Liquid Interface to Model Lung Infections.

Journal of proteome research·2026
Same author

Adjuvant combination and antigen multimerization shape neutralizing antibody and T cell responses to a SARS-CoV-2 RBD subunit vaccine.

Frontiers in immunology·2025
Same author

Murine antibody 4B1D3 exhibits broad cross-reactivity and neutralizing activity against SARS-CoV-2 variants.

Virology·2025
Same author

Protective role of anti-SARS-CoV-2 antibody responses against vital organ related long COVID symptoms.

Scientific reports·2025
Same author

Corrigendum: Anti-RBD IgG antibodies from endemic coronaviruses do not protect against the acquisition of SARS-CoV-2 infection among exposed uninfected individuals.

Frontiers in immunology·2025
Same journal

Resolution Biology in Soft Tissue Joint Disease.

Current topics in microbiology and immunology·2026
Same journal

A 25+ Year Journey on Yeast-Regulated Cell Death Research.

Current topics in microbiology and immunology·2026
Same journal

Adoptive T-Cell Immunotherapy.

Current topics in microbiology and immunology·2026
Same journal

Resolution Pharmacology Targeting the Melanocortin System.

Current topics in microbiology and immunology·2026
Same journal

Resolution of Skeletal Muscle Inflammation: Role of Specialized Pro-resolving Lipid Mediators in the Recovery from Exercise, Injury, and Disease.

Current topics in microbiology and immunology·2026
Same journal

Epstein-Barr Virus: From the Detection of Sequence Polymorphisms to the Recognition of Viral Strains.

Current topics in microbiology and immunology·2026
See all related articles

Related Experiment Video

Updated: Sep 11, 2025

Multiplexed Isothermal Amplification Based Diagnostic Platform to Detect Zika, Chikungunya, and Dengue 1
06:18

Multiplexed Isothermal Amplification Based Diagnostic Platform to Detect Zika, Chikungunya, and Dengue 1

Published on: March 13, 2018

14.4K

Dengue Vaccines.

Silvia Beatriz Boscardin1

  • 1Departamento de Parasitologia, Instituto de Ciências Biomédicas, Universidade de São Paulo, São Paulo, Brazil. sbboscardin@usp.br.

Current Topics in Microbiology and Immunology
|August 12, 2025
PubMed
Summary
This summary is machine-generated.

Developing effective dengue vaccines faces challenges due to the virus's four serotypes and antibody-dependent enhancement (ADE). This review covers vaccine candidates, clinical trial lessons, and future research for a universal dengue vaccine.

Keywords:
Antibody-dependent enhancement (ADE)Dengue vaccinesSerotype-specific immunityTetravalent protectionVaccine efficacy

More Related Videos

A Murine Model of Dengue Virus-induced Acute Viral Encephalitis-like Disease
04:23

A Murine Model of Dengue Virus-induced Acute Viral Encephalitis-like Disease

Published on: April 28, 2019

6.7K
Author Spotlight: Development of a Smartphone-Enhanced Paper-Based Device for Rapid Dengue NS1 Detection
06:00

Author Spotlight: Development of a Smartphone-Enhanced Paper-Based Device for Rapid Dengue NS1 Detection

Published on: January 26, 2024

1.5K

Related Experiment Videos

Last Updated: Sep 11, 2025

Multiplexed Isothermal Amplification Based Diagnostic Platform to Detect Zika, Chikungunya, and Dengue 1
06:18

Multiplexed Isothermal Amplification Based Diagnostic Platform to Detect Zika, Chikungunya, and Dengue 1

Published on: March 13, 2018

14.4K
A Murine Model of Dengue Virus-induced Acute Viral Encephalitis-like Disease
04:23

A Murine Model of Dengue Virus-induced Acute Viral Encephalitis-like Disease

Published on: April 28, 2019

6.7K
Author Spotlight: Development of a Smartphone-Enhanced Paper-Based Device for Rapid Dengue NS1 Detection
06:00

Author Spotlight: Development of a Smartphone-Enhanced Paper-Based Device for Rapid Dengue NS1 Detection

Published on: January 26, 2024

1.5K

Area of Science:

  • Virology
  • Immunology
  • Vaccinology

Background:

  • Dengue virus presents complex challenges for vaccine development, including four distinct serotypes.
  • Antibody-dependent enhancement (ADE) is a critical factor influencing dengue vaccine design and efficacy.
  • Developing effective dengue vaccines requires overcoming hurdles such as suitable animal models and viral interference.

Purpose of the Study:

  • To provide an overview of dengue vaccine candidates that have progressed to clinical trials.
  • To address the complexities and challenges inherent in dengue vaccine development.
  • To analyze the efficacy, safety, and lessons learned from clinical trials of leading dengue vaccine candidates.

Main Methods:

  • Review of historical and current dengue vaccine candidates.
  • Analysis of clinical trial data for efficacy and safety profiles.
  • Discussion of developmental challenges, including viral characteristics and experimental models.

Main Results:

  • Several dengue vaccine candidates, including Dengvaxia®, Qdenga®, and Butantan-DV, have advanced to clinical trials.
  • Clinical trials have provided valuable insights into vaccine efficacy, safety, and the impact of ADE.
  • Significant hurdles remain, including the need for improved animal models and strategies to mitigate viral interference.

Conclusions:

  • Advancements in dengue vaccine development have been made, but challenges persist.
  • Lessons from clinical trials are crucial for refining future vaccine strategies.
  • Further research is essential to achieve a universally effective dengue vaccine.